ActiGraph

?? In oncology drug development, regulators have highlighted the need for clinical trials to not only include survival and tumor-centric endpoints, but also those demonstrating a clinical benefit including physical function, quality of life, and symptom improvement. ?? Our Patient-Focused Digital Measures Library is a resource that highlights opportunities for wearable DHTs to provide patient-centric measures for use in clinical trials. Cancer can impact patients' physical function, energy, and sleep, and side effects from treatments can also have a negative impact on quality of life. Visit the library ??https://hubs.la/Q03bKVZm0 Oncology-related reports available in the library include - ?? Cancer Cachexia ?? Breast Cancer ?? Low Grade Serous Ovarian Cancer ?? Lung Cancer ?? Reducing Cardiac Late Effects in Pediatric Cancer Survivors ?? Xerostomia Each report leverages information from the FDA's Patient-Focused Drug Development meetings to summarize patient experiences and highlight how digital health technologies (DHTs) can track and measure aspects of health that are meaningful to patients' quality of life. Our goal with these reports is to help facilitate the use of digital health technologies to advance treatments for oncology patients. #Oncology #ClinicalTrials #DigitalMeasures #DHT #DigitalHealth #PatientFocusedDrugDevelopment

?? Are traditional efficacy measurements in neurology trials missing critical patient insights? Learn more about new opportunities in neurology research in our upcoming Digital Health Monthly webinar on March 26th at 12PM ET, where we’ll discuss: ?? How combining active and passive monitoring with DHTs can enhance the sensitivity of outcome measures in Parkinson’s disease, Alzheimer’s disease, and Multiple Sclerosis research ?? Strategies to integrate real-world patient function data into your clinical trials for more accurate assessments Register today! https://hubs.la/Q03bl9pP0 Speakers: Shibeshih Mitiku Belachew, MD, PhD, Chief Medical Officer, Indivi Moderator: Lindsey Snyder, PhD, Scientific Content Strategist, #ActiGraph #DigitalHealthTechnology #DHT #DigitalMeasures #DigitalEndpoints #Neurology #ParkinsonsDisease #AlzheimersDisease #MultipleSclerosis #DrugDevelopment #ClinicalTrials

Our acquisition of the Biofourmis Connect life sciences platform meant that we expanded our scientific and technical capabilities AND our team! ?? ?? We were so excited to have our newly formed ActiGraph India team come together for the grand opening of our new office space in Bengaluru. This was the first time our two India team joined together in networking, collaboration and celebration of many great thing to come. The team had the opportunity for some fun team building and even hosted our annual company meeting from India, where we connected virtually with our team from around the world to align on our mission and goals. ?? Together, we are pioneering the digital transformation of clinical research. And we couldn’t ask for a better team to support this mission! #ActiGraph #Teamwork

?? We're looking forward to MDA 2025 March 16-19 in Dallas, TX! If you're attending, please stop by our posters in the Exhibit Hall: ?? Assessing the accuracy of DHT-derived gait measures in amyotrophic lateral sclerosis: an analytical validation study ?? Assessing gait using wearable digital health technologies in Spinal Bulbar Muscular Atrophy: an analytical validation study If you're interested in learning how continuous, objective digital data collected with wearable DHTs can support your research, we'd love to speak with you about your study! ?? Reach out to our team who will be attending the meeting, Rakesh Pilkar and Sean Smith, or click here to set up a meeting: https://hubs.la/Q039XP700 #MDA2025 #NeuromuscularDisorders #ALS #SBMA #DigitalHealthTechnology #DHT #Wearables #DigitalMeasures #Gait

?? Physical activity, ??mobility, ??sleep, and ??cough are meaningful to oncology patients’ quality of life - and frequently correlate with improved outcomes. Continuous, objective, and quantitative digital measures of patient functioning can help oncology researchers: ?? Demonstrate meaningful, patient-centric benefits ?? Make informed, data-based decisions Visit our new Solutions for Oncology Research page to learn more and access additional resources related to the use of digital endpoints in oncology: ?? https://hubs.la/Q039PK5P0 #Oncology #CancerResearch #ClinicalTrials #DigitalMeasures #DigitalEndpoints #PhysicalActivity #Mobility #Sleep #Cough #PatientFocusedDrugDevelopment

Despite a robust development pipeline in Parkinson's disease and Alzheimer's disease, many of these treatments fail to transition from Phase 2 to Phase 3 trials, raising the question – are these treatments ineffective, or are the current efficacy measurements not sensitive enough? Join us for our next Digital Health Monthly webinar discussing a new scientific partnership between #ActiGraph and Indivi combining both active and passive digital measures for a more comprehensive view of patients' capacity, perception, and performance that is critical for evaluating new therapies. Register here ??https://hubs.la/Q039tTD-0 Speakers: Shibeshih Mitiku Belachew, MD, PhD, Chief Medical Officer, Indivi Moderator: Lindsey Snyder, PhD, Scientific Content Strategist, ActiGraph ??? Wednesday, March 26th ?? 12:00 PM ET Don't miss this opportunity to stay at the forefront of neurology drug development. #DigitalHealthMonthly #DHT #DigitalMeasures #Neurology #Parkinsonsdisease #Alzheimersdisease #ClinicalTrials #DrugDevelopment

It was a joy to host our leadership team Jeremy Wyatt, Michael Kicak, CPA, CGMA and Christian McCants in India. Team India was thrilled to meet each other and engage with the leadership, even if only for a short time. A heartfelt thank you to Jeremy, Mike, and Chris for taking the time to connect with everyone and for answering all our questions—whether insightful or just plain fun! A big shoutout to?Swapan Gupta for being the voice of reason amidst the excitement.?Special thanks to Madhumitha Jothirajan for being the perfect host, ensuring gifts were in place while juggling a million other things.? Huge appreciation to?Ramya Nelli for making the office look fantastic and to Ali Imran Alangayam for all the support behind the scenes. We certainly missed Scott Ginnetti :(. Looking forward to more such inspiring meetups! Being the undeniable movie buff that I am, I couldn’t resist creating a little memory capsule! ActiGraph #IndiaMeet #FunWeek

Last month, we held our 3rd ActiGraph Digital Data Summit, bringing together clinical researchers who are passionate about advancing the use digital health to improve clinical research. ?? It was exciting to see the work presented and the conversations it inspired take a clear step forward. ?? In this issue, we give some examples of this exciting progress using digital health technology to provide unique clinical insights in areas such as immunology and immunotherapy. We also share more details on how ActiGraph's expanded technology and scientific products support our customers more broadly through patient-focused digital data. #DigitalHealthTechnology #Immunology #AutoimmuneDisease #Immunotherapy #Oncology #CancerCare #ADDS2025 #NHANES #HIMSS25 #MDA2025

A single rare disease affects a small percent of the population, but collectively there are over 6,000 different rare diseases. These rare diseases affect over 300 million people worldwide, which equals the population of the world's 3rd largest country. ???Today, we'd like to contribute to raising awareness of rare diseases and the impact they have on patients' lives, and thank everyone who is working towards helping to advance treatments for these conditions. Learn more about the impact of rare diseases at ??https://hubs.la/Q038RrBg0 Many of the FDA's Patient-Focused Drug Development Meeting Reports summarize the views of patients with rare diseases, including what symptoms have the most significant impact on their lives and their perspectives on treatments. Understanding what matters to patients with rare diseases helps us develop more effective and meaningful treatments. ?? In our Patient-Focused Digital Measures Library, we've summarized the most significant symptoms reported by patients and how digital health technologies can measure these meaningful aspects of health to help evaluate new treatments for rare diseases such as amyotrophic lateral sclerosis (ALS), myotonic dystrophy (DM), spinal muscular atrophy (SMA), Kennedy's disease, narcolepsy, idiopathic pulmonary fibrosis, and inclusion body myositis: https://hubs.la/Q038Rs1l0 We hope to continue bringing awareness to the impact of rare diseases and help to advance therapies for patients with these conditions. #RareDiseaseDay2025

??♂? Physical activity is one of the key factors in sustaining weight loss, preserving muscle mass, and achieving long-term health benefits. Read the recent article in pharmaphorum by Christine Cong Guo to learn more about how adding objective measures of physical activity to clinical trials can help us better understand the influence of medication and lifestyle factors on weight loss and muscle mass, providing more robust data on treatment effects. ?? ??https://hubs.ly/Q038sMp40 #Obesity #DrugDevelopment #GLP1 #PhysicalActivity #DigitalMeasures #WeightLoss #MuscleMass #HealthBenefits